No. 327Germany
Thomas Struengmann & family
Pharmaceuticals · Tegernsee
Net worth
$10.8B
Today
+$16M+0.15%Past month
−$432M−3.84%As of Nov 11, 2026, 1:50 PM EST
Thomas Struengmann and twin brother Andreas were early backers of German firm BioNTech, which partnered with Pfizer to make a vaccine for Covid-19. The brothers cofounded generic drugmaker Hexal in 1986 and sold it to Novartis in 2005 for some $7 billion. The brothers invest in biotech, pharma, life sciences and healthcare companies through their Zug, Switzerland-based investment firm, Santo Holding. In 2008, they established a neuroscience research center in Frankfurt named after their father, Ernst Struengmann.
Net worth over time
−3.84%−$432M over the past month
$11B$11B$11B
Oct 12Nov 11
Principal holdings
3 positions| Company | Industry | Share | Value |
|---|---|---|---|
Private and other holdings | Healthcare | 58.8% | $6.4B |
BioNTech Sponsored ADR NASDAQ: BNTX | Healthcare | 40.9% | $4.4B |
Formycon AG XETRA: FYB-DE | Healthcare | 0.3% | $35M |
Also known for
- After obtaining a business degree from the University of Augsburg, Thomas worked as a marketing manager for Schering-Plough.
- Like his brother, an identical twin, he is said to be an accomplished golfer and likes to ski. He reportedly collects modern art and Swiss watches.